Please ensure Javascript is enabled for purposes of website accessibility

Why DBV Technologies Stock Is Plunging Today

By Prosper Junior Bakiny – Updated Aug 4, 2020 at 12:08PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA rejected the company’s application for its peanut-allergy patch.

What happened?

Shares of DBV Technologies (DBVT 3.11%) were down a whopping 41.6% as of 11:41 a.m. EDT on Tuesday. The catalyst for this sell-off was the company's announcement that it has received a complete response letter from the Food and Drug Administration regarding its Biologics License Application (BLA) for Viaskin, a potential treatment for peanut allergy.  

So what

Viaskin is a patch designed to desensitize a patient's immune system by exposing the patient to increased amounts of peanut protein. But the FDA has questioned the effect of patch adhesion on the efficacy of Viaskin, and the agency requested additional data to clear up this issue. DBV Technologies complied with this request, but it seems it wasn't enough to please the FDA. This morning, the France-based biotech reported that the FDA would not approve Viaskin's BLA "in its present form." 

Man holding his head in panic.

Image source: Getty Images.

If DBV Technologies hopes to launch Viaskin on the market, it will have to make some modifications to its patch, do some more testing with this modified version of Viaskin, and submit clinical data to the FDA. At this point, no one knows how long this will take. The company will meet with the FDA to discuss the next steps in this process.

Daniel Tassé, CEO of DBV Technologies, said, "We are very disappointed in the FDA's response, but continue to believe in the potential of Viaskin Peanut."

Now what 

DBV doesn't have any products on the market at the moment, which means the company had a lot riding on its BLA for Viaskin, especially considering the high prevalence of peanut allergy both in the U.S. and abroad. Given this factor, it isn't surprising that investors sold off shares of the biotech stock following today's news. And considering the uncertainty surrounding Viaskin, it may not be wise to buy shares of DBV Technologies right now. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

DBV Technologies S.A. Stock Quote
DBV Technologies S.A.
$1.99 (3.11%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.